摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-hydroxy-3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione | 871302-55-5

中文名称
——
中文别名
——
英文名称
2-(2-hydroxy-3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione
英文别名
2-{2-Hydroxy-3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-isoindole-1,3-dione;2-[2-hydroxy-3-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione
2-(2-hydroxy-3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione化学式
CAS
871302-55-5
化学式
C24H33N3O4
mdl
——
分子量
427.544
InChiKey
HEWYPHBNNUFUOW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    73.3
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS
    申请人:Salman Mohammad
    公开号:US20090312344A1
    公开(公告)日:2009-12-17
    The present invention relates to α 1 , and/or α 1d adrenergic receptor antagonists, which can function as α 1a and/or α 1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α 1a and/or an adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.
    本发明涉及α1和/或α1肾上腺素受体拮抗剂,其可以作为α1a和/或α1d肾上腺素受体拮抗剂,可用于治疗通过α1a和/或肾上腺素受体介导的疾病或紊乱。本文所披露的化合物可用于治疗良性前列腺增生症(BPH)及其相关症状。此外,本文所披露的化合物可用于治疗与或不伴随BPH的下尿路症状。还提供制备此类化合物的方法,其制药组合物以及治疗BPH或其相关症状的方法。
  • WO2006/92710
    申请人:——
    公开号:——
    公开(公告)日:——
  • ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS
    申请人:Ranbaxy Laboratories Limited
    公开号:EP1758583A2
    公开(公告)日:2007-03-07
  • [EN] ADRENERGIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS ADRENERGIQUES
    申请人:RANBAXY LAB LTD
    公开号:WO2005118537A2
    公开(公告)日:2005-12-15
    The present invention relates to α1a and/or α1d adrenergic receptor antagonists of formula (I), which can function as α1a and/or α1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α1a and/or α1d adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.
  • [EN] METABOLITES OF 2-{3-[4-(2-ISOPROPOXYPHENYL) PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE<br/>[FR] METABOLITES DE LA 2-{3-[4-(2-ISOPROPOXYPHENYL)PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE
    申请人:RANBAXY LAB LTD
    公开号:WO2006092710A1
    公开(公告)日:2006-09-08
    [EN] The present invention relates to the metabolites of 2-3-[4-(2-isopropoxyphenyl) piperazin-1-yl]-propyl}-3a,4,7,7a -tetrahydro-1H-isoindole-1,3(2H)-dione of Formula I. The disclosed compounds can function as 1a-adrenoceptor antagonists and thus can be used for the treatment of benign prostatic hyperplasia (BPH) and related symptoms thereof. Processes for preparing the metabolites, pharmaceutical composition containing these metabolites and the method of treating BPH and related symptoms thereof are also provided.
    [FR] La présente invention concerne les métabolites de la 2-3-[4-(2-isopropoxyphényl)pipérazin-1-yl]-propyl}-3a,4,7,7a-tétrahydro-1H-isoindole-1,3(2H)-dione répondant à la formule I. Les composés décrits peuvent fonctionner en tant qu'antagonistes des récepteurs 1a-adrénergiques et peuvent donc être utilisés pour le traitement de l'hypertrophie bénigne de la prostate (HBP) et des symptômes apparentés. L'invention décrit également des procédés pour préparer les métabolites, une composition pharmaceutique contenant ces métabolites et le procédé de traitement de l'HBP et des symptômes apparentés.
查看更多